epirubicin

This case suggests that a BRCA2 reversion mutation can arise early, even before PARPi or platinum exposure. Serial monitoring of BRCA status may help predict therapeutic resistance in patients with germline BRCA-mutated breast cancer.

PEF NDs had no detrimental effects on vital organs (heart, kidney, liver, lung, or spleen), indicating acceptable in vivo biosafety. Self-assembled nanodrugs with simultaneous photothermal and anti-inflammatory properties have considerable clinical potential in the treatment of metastatic malignancies.

P=N/A, N=43, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=356, Recruiting, Universitaire Ziekenhuizen KU Leuven | Not yet recruiting --> Recruiting | Trial completion date: Mar 2031 --> Sep 2031 | Trial primary completion date: Mar 2028 --> Sep 2028

Patients with c/pN2-3 or G3 with Ki67 >40% were randomized directly to CTx subtrial evaluating (neo)adjuvant paclitaxel vs. nab-paclitaxel, followed by epirubicin + cyclophosphamide and ET...Assuming a hazard ratio of 0.7 for a ribociclib effect in NATALEE, an absolute benefit of approximately 2% fewer dDFS events after 5 years could be expected in this group based on the WSG-ADAPT-HR+/HER2- experience. ET-response evaluation can refine prognosis to better inform shared decision-making in this intermediate-risk group.

Based on trace Mycobacterium tuberculosis detection on sputum GeneXpert with indeterminate rifampicin resistance, the patient was initially diagnosed and treated as tuberculous pericarditis...The patient received first-line chemotherapy with ifosfamide and epirubicin...Second-line chemotherapy with nab-paclitaxel and gemcitabine was subsequently initiated, with planned response assessment after 3 cycles...Although substantial initial responses to chemotherapy may occur, the disease remains highly aggressive with a high risk of progression. Early histopathological diagnosis and timely initiation of adaptive, multimodal treatment strategies are critical to optimizing clinical outcomes.

Interestingly, Asphere demonstrates nearly quantitative loading of both epirubicin (EPI) and ACF within 1 min, while achieving sustained release of the dual drugs over 8 weeks...In preclinical studies, EA@Asphere significantly suppresses hypoxia-associated protein expression, enhances immunogenic cell death, promotes dendritic cell maturation, and reprograms tumor microenvironment, achieving significant inhibition of the tumor progression and metastasis. These findings offer transformative potential to improve clinical outcomes in advanced HCC, holding broad interest for researchers and clinicians in oncology and drug delivery.

In this study, a radiation recall-like dermatitis model (RRLD) was established in Sprague-Dawley rats by localized skin irradiation followed by subcutaneous administration of non-toxic concentrations of chemotherapeutic agents, including 5-fluorouracil (5-Fu, 10 µg/µL) or Epirubicin (EPI, 0.05 µg/µL), into the irradiated area. Consistently, rescue experiments using an Akt activator (SC79) partially restored p-Akt and Bcl2 expression and markedly reduced apoptotic responses, supporting the functional relevance of this pathway in RRLD. Collectively, these findings indicate that miR-338-3p acts as a critical epigenetic regulator of RRLD through modulation of the PTN/PI3K/Akt/Bcl2 axis and suggest that this molecular circuit represents a promising therapeutic target for mitigating clinical radiation recall-associated skin injury.

P=N/A, N=43, Enrolling by invitation, Eye & ENT Hospital of Fudan University

P=N/A, N=324, Completed, First Affiliated Hospital, Sun Yat-Sen University

P2, N=30, Recruiting, Affiliated Hospital of Nantong University | Not yet recruiting --> Recruiting

P3, N=1800, Not yet recruiting, Shanghai JMT-Bio Inc.